FUJIFILM Diosynth Biotechnologies recently announced that TG Therapeutics, Inc. has committed to a multi-year manufacturing supply agreement for BRIUMVI? its U.S. FDA-approved therapeutic for relapsing forms of multiple sclerosis. FUJIFILM Diosynth Biotechnologies to provide #biopharmaceutical manufacturing support from its facility in Holly Springs, North Carolina, which is set to be fully operational in 2025. Learn more here: https://brnw.ch/21wOmCv
FUJIFILM Holdings America Corporation的动态
最相关的动态
-
Senior Platform Director @ Corden Pharma on a mission to enable development of Innovative Solution to support LNP formulation | Executive MBA with Peptides, Lipids expertise
The LNP starter kits are meant to facilitate easy formulation screening, enabling the generation of LNPs capable of providing efficient transfection in different cell types, including immortalized and/or primary cell cultures. The kits, which can be used for animal?in-vivo?applications including PK/PD studies and mRNA transfection efficacy POC/studies, have been tested in our LNP manufacturing site with GFP-mRNA as cargo, and successfully implemented for synthetic RNAs (such as siRNA) and DNA as well. The LNP Kits consist of both well-known and characterized formulations in a preclinical and clinical setting, (e.g. COVID-19 Vaccines), with various combinations available to benchmark / compare LNP formulations or create completely novel compositions that elevate formulations to the next level during screening phases. #mRNA #Lipids #vaccines #CordenPharma #Innovation #LNP #COVID
Umberto Romeo, Development Director of the Lipid Nanoparticle Manufacturing area at our facility in Caponago (IT), explains how the kits support researchers and developers with the essential components needed to create and optimize their own LNPs for #mRNA delivery. The benefits of our kits include: -Customization and optimization of lipid composition and formulation parameters tailored to specific mRNA-based therapeutics -Cost effectiveness -Rapid prototyping -Intellectual property control Take advantage of our 25% discount by ordering our kits before the end of June 2024. Order here:?https://lnkd.in/eTK2ZSPj #cordenpharma #lipidnanoparticles #lnps #cdmo #pharmaceuticals #pharma #pharmaindustry
-
Thoughts on this? >> Incyte drops four early-stage programs from its pipeline as part of strategic review >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #healthcare #biotech #productmarketing
Incyte drops four early-stage programs from its pipeline as part of strategic review
endpts.com
-
New Tools and Solutions for Oligio's ....
Access this on-demand webinar to get valuable insights into biopharmaceutical drug development. You'll learn about state-of-the-art solutions that support the entire workflow employed by Contract Drug Manufacturing Organizations (CDMOs), from R&D to validation and manufacturing. Watch it here: https://lnkd.in/epDktkEJ #oligonucleotides #biopharma #pharma #analyticalinstruments #shimadzu
Towards the Future of Biopharma: Insights into Oligonucleotide Therapeutics
https://www.youtube.com/
-
PD-(L)1 Inhibitors Top Abstracts about to reveal at ASCO 2024 At ASCO 2024, leading pharmaceutical giants including AstraZeneca, Merck, Bristol Myers Squibb, BeiGene, AkesoBio, Hengrui Pharma Co.,Ltd, and Qilu Pharmaceuticals are poised to unveil initial, updated, and final findings. The forthcoming session generates high anticipation as it will reveal primary results from the Phase III CheckMate-9DW study, aiming to introduce a potential treatment avenue for enhancing outcomes in hepatocellular cancer, potentially surpassing established tyrosine kinase inhibitors. Notably, results from bi-specific PD-1 inhibitors like Acasunlimab (PD-1 X 4-1BB) and IBI363 (PD-1 and IL-2) will draw considerable attention. Moreover, insights from Chinese pharmaceutical companies are eagerly awaited as well. Unlock Exclusive Expert Insights and Comprehensive Analysis of ASCO 2024 with DelveInsight Business Research LLP @ https://lnkd.in/g-Qht2Qp #ASCO2024 #PharmaUpdates #ClinicalTrials #CheckMate9DW #HepatocellularCancer #BiSpecificInhibitors #MedicalResearch #CancerTreatment #BiotechNews #ChinesePharma
PD-(L)1 Inhibitors Top Abstracts | ASCO 2024
delveinsight.com
-
Passionate communications leader with 20+ years of experience in corporate, agencies and a foundation. Unique combination of strategic thinking, creativity and execution of large scale programs.
Interested to learn what`s next in R&D@BMS? Click on the link below to read a Q&A with Robert Plenge, our Head of Research.
Together, the three pillars of our research framework and differentiated platforms, targeted #ProteinDegradation, #CellTherapy and radiopharmaceutical therapeutics (RPTs), enable our teams around the world to deliver transformative and high-quality medicines with an increased probability of success. Our Head of Research, Robert Plenge, outlines the strategy and his vision for what’s next in R&D: https://bit.ly/3Vmh1Y1
-
PD-(L)1 Inhibitors Top Abstracts about to reveal at ASCO 2024 At ASCO 2024, leading pharmaceutical giants including AstraZeneca, Merck Healthcare, Bristol Myers Squibb, BeiGene, Akeso, Hengrui Pharma Co.,Ltd, and Qilu Pharmaceuticals are poised to unveil initial, updated, and final findings. The forthcoming session generates high anticipation as it will reveal primary results from the Phase III CheckMate-9DW study, aiming to introduce a potential treatment avenue for enhancing outcomes in hepatocellular cancer, potentially surpassing established tyrosine kinase inhibitors. Notably, results from bi-specific PD-1 inhibitors like Acasunlimab (PD-1 X 4-1BB) and IBI363 (PD-1 and IL-2) will draw considerable attention. Moreover, insights from Chinese pharmaceutical companies are eagerly awaited as well. Unlock Exclusive Expert Insights and Comprehensive Analysis of ASCO 2024 with DelveInsight Business Research LLP - https://lnkd.in/gb4amxnj #ASCO24 #ASCO2024 #PharmaUpdates #ClinicalTrials #CheckMate9DW #HepatocellularCancer #BiSpecificInhibitors #MedicalResearch #CancerTreatment #BiotechNews #ChinesePharma #pd1 #inhibitors #Acasunlimab
PD-(L)1 Inhibitors Top Abstracts | ASCO 2024
delveinsight.com
-
Chairman & CEO of Mira ($MIRA) and Telomir ($TELO) Pharmaceuticals. Innovating treatments for neuropsychiatric disorders and extending lifespan
??$MIRA MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments in Preclinical Study?? We’re excited to share that our novel oral ketamine analog, Ketamir-2, demonstrated promising results in a recent preclinical study, showing greater effectiveness compared to established treatments like Gabapentin (Neurontin) and Pregabalin (Lyrica). Based on these new findings, we feel very optimistic about Ketamir-2's potential to address unmet needs in pain management and beyond. Stay tuned for more updates as we work to bring this innovative therapy closer to patients in need. ?? #biotech #neuropathicpain #pharmaceuticals #clinicaltrials #Ketamir2 #PTSD #innovation #MiraPharma #NASDAQ #MIRA #FDAapproved https://lnkd.in/eUwz-CTP
-
-
In a recent interview with Innovations in Pharmaceutical Technology Yama Abassi from Agilent Technologies spoke about the evolution of immune-oncology, gaps in existing cell analysis tools, and his outlook of adoptive cell therapies in the next decade. Read the article: Real time cell analysis (iptonline.com)
-
